

ESTIMATED ANNUALIZED BURDEN HOURS

Respondents	Instrument type	No. of respondents	No. of responses per respondent	Average burden per respondent (in hours)
Eligible participants .....	Baseline questionnaire .....	40	1	20/60
	Symptom survey .....	40	5	2/60
	Scripted commute data collection .....	40	2	2

Dated: May 5, 2010.  
**Maryam I. Daneshvar,**  
*Reports Clearance Officer, Centers for Disease Control and Prevention.*  
 [FR Doc. 2010-11180 Filed 5-10-10; 8:45 am]  
**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Office of the Director; Notice of Charter Renewal for the National Science Advisory Board for Biosecurity**

In accordance with Title 41 of the U.S. Code of Federal Regulations, Section 102-3.65(a), notice is hereby given that the Charter for the National Science Advisory Board for Biosecurity (NSABB) was renewed for an additional two-year period on April 7, 2010.

It is determined that NSABB is in the public interest in connection with the performance of duties imposed on the Department of Health and Human Services by law, and that these duties can best be performed through the advice and counsel of this group.

Inquiries may be directed to Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy, Office of the Director, National Institutes of Health, 6701 Democracy Boulevard, Suite 1000, Bethesda, Maryland 20892 (Mail code 4875), Telephone (301) 496-2123, or [spaethj@od.nih.gov](mailto:spaethj@od.nih.gov).

Dated: May 4, 2010.  
**Jennifer Spaeth,**  
*Director, Office of Federal Advisory Committee Policy.*  
 [FR Doc. 2010-11043 Filed 5-10-10; 8:45 am]  
**BILLING CODE 4140-01-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Government-Owned Inventions; Availability for Licensing**

**AGENCY:** National Institutes of Health, Public Health Service, HHS.  
**ACTION:** Notice.

**SUMMARY:** The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**ADDRESSES:** Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

**Erythroid Progenitor Cell Line for Hematological Disease Applications**

*Description of Invention:* *Plasmodium vivax* (malaria) is a significant health concern in many parts of Asia, Latin America, North Africa, and the Middle East. There is a lack of continuous culture systems for this pathogen. The subject technology is an erythroid progenitor continuous cell line (termed CD36E) identified by erythroid markers CD36, CD33, CD44, CD71, CD235, and globoside. These CD36E cells are heterozygous for Fya and Fyb (Duffy antigen). Due to recent evidence that *Plasmodium vivax* (*P. vivax*) can infect erythroid progenitor cells (reference: YX Ru *et al.* and T Panichakul *et al.*), these cells can be potentially used for culturing *P. vivax* and other species of malaria. This in turn could aid development of malaria related treatments and/or products. In addition, the cell line can also be used for other hematological disease applications that involve red blood cells or red blood cell precursors. The CD36E cells also produce alpha, beta, and chi hemoglobin and therefore may be used for research involving hemoglobin.

*Applications:*

- Culture system for *Plasmodium* species (malaria)
  - Hematological diseases
- Advantages:* Immortalized erythroid progenitor cell line.  
*Development Status:* *In vitro* data can be provided upon request.

- Market:*
- Malaria
  - Anti-malaria drug screening
  - Hematological diseases
  - Hemoglobin

*Inventors:* Susan Wong, Neal S. Young, Ning Zhi (NHLBI).

*Relevant Publications:*

1. YX Ru *et al.* Invasion of erythroblasts by *Plasmodium vivax*: A new mechanism contributing to malarial anemia. *Ultrastruct Pathol.* 2009 Oct;33(5):236-242. [PubMed: 19895296].

2. T Panichakul *et al.* Production of erythropoietic cells in vitro for continuous culture of *Plasmodium vivax*. *Int J Parasitol.* 2007 Dec;37(14):1551-1557. [PubMed: 17610880].

*Patent Status:* HHS Reference No. E-151-2010/0—Research Tool. Patent protection is not being pursued for this technology.

*Licensing Status:* Available for biological materials licensing.  
*Licensing Contact:* Kevin W. Chang, Ph.D.; 301-435-5018; [changke@mail.nih.gov](mailto:changke@mail.nih.gov).

*Collaborative Research Opportunity:* The National Heart Lung and Blood Institute, Hematology Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the CD36E cell line. Please contact Cecilia Pazman, Ph.D., at [pazmance@mail.nih.gov](mailto:pazmance@mail.nih.gov) for more information.

**Parvovirus B19 Codon Optimized Structural Proteins for Vaccine and Diagnostic Applications**

*Description of Invention:* Parvovirus B19 (B19V) is the only known pathogenic human parvovirus. Infection by this viral pathogen can cause transient aplastic crisis in individuals with high red cell turnover, pure red cell aplasia in immunosuppressed patients, and hydrops fetalis during